Press Releases

Date Title and Summary View
Toggle Summary Oxford Immunotec Schedules First Quarter 2017 Earnings Release and Conference Call for May 2, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 19, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated
View HTML
Toggle Summary Oxford Immunotec Announces Release of New National Tuberculosis Test Data and Screening Grant for High Risk Patients on World TB Day
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 23, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Reports Fourth Quarter and Full Year 2016 Financial Results
Fourth quarter revenue of $23.7 million, an increase of 41% compared to prior year period Fourth quarter Tuberculosis revenue of $20.4 million, an increase of 22% compared to prior year period Fourth quarter Tick-borne disease and other revenue of $3.3 million Full year 2016 revenue of $86.1
View HTML
Toggle Summary Oxford Immunotec to Present at the Cowen and Company 37th Annual Health Care Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated
View HTML
Toggle Summary Oxford Immunotec Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call for February 28, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec to Present at the Leerink Partners 6th Annual Global Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated
View HTML
Toggle Summary Oxford Immunotec to Present at the 35th Annual J.P. Morgan Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated
View HTML
Toggle Summary Oxford Immunotec Announces New England Journal of Medicine Publication on Clinical Trial Results of Serological and Nucleic Acid Tests for Babesia in Blood Screening
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec to Present at the 28th Annual Piper Jaffray Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Ranked Among Deloitte's 2016 Technology Fast 500™
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions today
View HTML